發(fā)布時(shí)間：2018-05-10 13:15

  本文選題：非布司他 + 高尿酸血癥��； 參考：《南昌大學(xué)》2015年碩士論文

【摘要】：目的:系統(tǒng)評(píng)價(jià)非布司他對(duì)比別嘌醇治療高尿酸血癥的療效與安全性。方法:檢索Pub Med、MEDLINE、ISI Web of knowledge、CNKI、CBM、萬(wàn)方等數(shù)據(jù)平臺(tái),檢索年限從2004年9月至2014年9月,納入非布司他及別嘌醇治療高尿酸血癥的隨機(jī)對(duì)照試驗(yàn),進(jìn)行質(zhì)量評(píng)價(jià),運(yùn)用Revman5.0軟件對(duì)兩藥治療高尿酸血癥的療效及安全性進(jìn)行Meta分析。結(jié)果:共納入7篇文獻(xiàn),截止至最后隨訪,非布司他組血清尿酸值達(dá)標(biāo)的患者比例明顯高于別嘌醇組(69.5%vs 43.6%;OR=3.38;95%CI,1.96-5.81;P0.01)。亞組分析顯示:非布司他40mg/d比別嘌醇100~300mg/d有更高比例的患者達(dá)到目標(biāo)血清尿酸值(50.6%vs 46.1%;OR=1.22;95%CI,1.02-1.45;P=0.03)。隨著非布司他劑量增加至(80、120mg/d),達(dá)到目標(biāo)血清尿酸值的患者比例明顯升高(分別為72.8%、82.0%)在副作用方面非布司他和別嘌醇沒(méi)有明顯的差距。結(jié)論:非布司他(40~120mg/d)比別嘌醇(100~300mg/d)降尿酸效果更好。安全性方面非布司他和別嘌醇相似。
[Abstract]:Objective: to evaluate the efficacy and safety of nonbuflast compared with allopurinol in the treatment of hyperuricemia. Methods: the data platforms such as Pub Medine MEDLINEISI Web of knowledge CNKICBM were searched. The retrieval period was from September 2004 to September 2014, and the quality evaluation was carried out in a randomized controlled trial of the treatment of hyperuricemia with non-Budestar and allopurinol. The efficacy and safety of two drugs in the treatment of hyperuricemia were analyzed by Meta software Revman5.0. Results: by the end of the last follow-up, the proportion of patients in the non-Budesta group who had met the level of serum uric acid was significantly higher than that in the allopurinol group (69.5 vs 43.6%). Subgroup analysis showed that a higher proportion of patients with 40mg/d than allopurinol 100~300mg/d reached the target serum uric acid value of 50.6 vs 46.1%. There was no significant difference in side effects between nonbusultan and allopurinol in side effects with the increase of the dose of non-busultan to 80120 mg / d, the proportion of patients who reached the target serum uric acid level increased significantly (72.8% 82.0, respectively). Conclusion: compared with allopurinol (100 mg / d), busultadine (40mg / d) is more effective than allopurinol (300mg / d) in reducing uric acid. In terms of safety, it is similar to allopurinol.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R589.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 段宇;劉超;;《高尿酸血癥和痛風(fēng)治療中國(guó)專家共識(shí)》解讀[J];國(guó)際內(nèi)分泌代謝雜志;2013年06期

2 王麗英;趙燕;鄭毅;李小霞;張曉;徐建華;吳華香;胡紹先;趙蔭環(huán);張風(fēng)肖;周彬;蘇厚恒;肖征宇;孫瑞華;王國(guó)春;;隨機(jī)雙盲三模擬對(duì)照多中心臨床研究非布索坦降低痛風(fēng)患者高尿酸水平的療效和安全性[J];中華臨床醫(yī)師雜志(電子版);2013年07期

3 周弋;齊慧;趙根明;楊黎明;孫喬;;上海市浦東新區(qū)居民高尿酸血癥與慢性腎病相關(guān)性研究[J];中華流行病學(xué)雜志;2012年04期

4 王德光;郝麗;戴宏;陳衛(wèi)東;張道友;李龍海;劉智;韓久懷;葉麗萍;白友為;;安徽省成人慢性腎臟病流行病學(xué)調(diào)查[J];中華腎臟病雜志;2012年02期

5 閻勝利;趙世華;李長(zhǎng)貴;王顏剛;王萍;王忠超;王芳;陳穎;王飛;苗志敏;;山東沿海居民高尿酸血癥及痛風(fēng)五年隨訪研究[J];中華內(nèi)分泌代謝雜志;2011年07期

6 鄒貴勉;黃江燕;車文體;眭維國(guó);董力;陳潔晶;向月應(yīng);鄒和群;;廣西城市社區(qū)居民高尿酸血癥流行病學(xué)調(diào)查及其與慢性腎臟病的關(guān)系[J];中華內(nèi)分泌代謝雜志;2011年07期

7 施桂英;;走出痛風(fēng)性關(guān)節(jié)炎診斷和治療的誤區(qū)[J];中華全科醫(yī)師雜志;2006年09期

，

本文編號(hào)：1869456